2 waves in Norway

3

7 8

9 10

20

22

24

27

- 4 Authors: Robert Whittaker (MSc) a*, Margrethe Greve-Isdahl (MD) a, Håkon Bøås (PhD) b,
- 5 Pål Suren (MD) ^c, Eirik Alnes Buanes (PhD) ^{d,e}, Lamprini Veneti (MSc) ^b
- 6 Family names are underlined.
 - a) Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway.
 - b) Department of Infection Control and Preparedness, Norwegian Institute of Public Health, Oslo, Norway.
- 11 c) Department of Child Health and Development, Norwegian Institute of Public Health, 12 Oslo, Norway.
- d) Department of Anaesthesia and Intensive Care, Haukeland University Hospital, Bergen, Norway.
- e) Norwegian Intensive Care and Pandemic Registry, Haukeland University Hospital, Bergen, Norway.
- * Corresponding author: Robert Whittaker, Norwegian Institute of Public Health,
- 18 Lovisenberggata 8, 0456, Oslo, Norway; Phone: +47 21 07 63 93; Email:
- 19 Robert. Whittaker@fhi.no
- 21 Short title: Severe outcomes by variant, COVID-19 cases <18, Norway
- 23 Conflict of interest: The authors declare that they have no competing interests.
- 25 Funding: This research was undertaken as part of routine work at the Norwegian Institute of
- 26 Public Health. No specific funding was received.
- 28 Abbreviations
- VOC: Variant of concern
- SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2
- COVID-19: Coronavirus disease
- MIS-C: Multisystem inflammatory syndrome in children
- LoS: Length of stay
- ICU: intensive care unit
- aRR: Adjusted risk ratio
- CI: Confidence interval
- PCR: Polymerase chain reaction
- 39 Article Summary

40 We compare the risk of severe outcomes in unvaccinated COVID-19 cases <18 years between waves of the SARS-CoV-2 Alpha, Delta and Omicron variant in Norway. 41 42 43 What's Known on This Subject Currently, limited evidence suggests no clear difference in the risk of severe disease outcomes 44 45 among children infected with different SARS-CoV-2 variants. The risk of multisystem 46 inflammatory syndrome in children following infection with the Omicron variant has not been 47 quantified. 48 49 What This Study Adds 50 We find a lower risk of hospitalisation due to acute COVID-19 among cases <1 year in the 51 Delta and Omicron waves compared to the Alpha wave, and a lower risk of multisystem 52 inflammatory syndrome in the Omicron wave, in Norway. 53

Word count: 2,990

Contributors' Statement Page

55

67

Robert Whittaker conceptualised and designed the study, contributed to data cleaning and 56 57 linkage between the different registries, conducted the data analysis, drafted the initial manuscript, and reviewed and revised the manuscript. Margrethe Greve-Isdahl and Pål Suren 58 59 conceptualised and designed the study, contributed interpretation of the results, and critically reviewed the manuscript. Håkon Bøås conceptualised and designed the study, contributed to 60 61 data cleaning and interpretation of the results, and critically reviewed the manuscript. Eirik 62 Alnes Buanes conceptualised and designed the study, coordinated data collection to the 63 Norwegian Intensive Care and Pandemic Registry, contributed to interpretation of the results, 64 and critically reviewed the manuscript. Lamprini Veneti conceptualised and designed the 65 study, contributed to data cleaning, assisted with the data analysis, contributed to 66 interpretation of the results, and critically reviewed the manuscript. All authors approved the

final manuscript as submitted and agree to be accountable for all aspects of the work.

Abstract

68

69

78

Objectives

- 70 We used linked individual-level data from national registries to compare the risk of severe
- outcomes among unvaccinated COVID-19 cases <18 years between waves of the SARS-
- 72 CoV-2 Alpha, Delta and Omicron variants in Norway.

73 Methods

- 74 Our outcomes were hospitalisation with acute COVID-19 or multisystem inflammatory
- syndrome in children (MIS-C). We calculated adjusted risk ratios (aRR) with 95% confidence
- 76 intervals (CIs) using multivariable log-binomial regression, adjusting for variant wave,
- 77 demographic characteristics and underlying comorbidities.

Results

- 79 We included 10,538 Alpha (21 hospitalised with acute COVID-19, 7 MIS-C), 42,362 Delta
- 80 (28 acute COVID-19, 14 MIS-C) and 82,907 Omicron wave cases (48 acute COVID-19, 7
- 81 MIS-C). The risk of hospitalisation with acute COVID-19 in cases <1 year was lower in the
- 82 Delta (aRR: 0.28, 95% CI: 0.16–0.89) and Omicron wave (aRR: 0.41, 95% CI: 0.20–0.81),
- compared to the Alpha wave. We found no difference in the risk for this outcome for Omicron
- 84 compared to Delta in any age group. The risk of MIS-C was lower in the Omicron wave
- 85 compared to the Alpha (aRR: 0.09, 95% CI: 0.03–0.27) and Delta wave (aRR: 0.26, 95% CI:
- 86 0.10–0.63).

87 Conclusions

- We found no evidence of a difference in the risk of hospitalisation due to acute COVID-19
- 89 among unvaccinated cases <18 years for Omicron compared to Delta, but a reduced risk
- among cases <1 year in Omicron and Delta waves, compared to Alpha. Results also suggest a
- 91 decrease in the risk of MIS-C in the Omicron wave compared to the Alpha and Delta waves.

Introduction

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

From late 2020, the emergence and global spread of variants of concern (VOC) (1) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have shaped the epidemiology of, and ongoing response to, the coronavirus disease (COVID-19) pandemic. More transmissible VOC have successively superseded their predecessors influencing transmission dynamics, viral virulence and vaccine effectiveness (2-8). The emergence of the Omicron variant (Phylogenetic Assignment of Named Global Outbreak Lineages (Pangolin) designation B.1.1.529) in November 2021 instigated a new wave of infections globally (9). Most children and adolescents with COVID-19 experience an asymptomatic or mild disease course. However, a small proportion may develop severe disease that requires hospitalisation. This may be due to acute COVID-19 or multisystem inflammatory syndrome in children (MIS-C), a postinfectious complication of SARS-CoV-2 infection. Death is rare (10, 11). There is currently limited evidence on whether the relative severity of COVID-19 in children differs when infected with different VOC. Previous studies from England (5) and Denmark (12) have not found clear evidence that the risk of hospitalisation among children and adolescents infected with Omicron differed compared to the Delta variant (Pangolin designation B.1.617.2). Preliminary data from the United States have suggested an increase in upper respiratory complications among children since Omicron became dominant (13, 14). Some studies comparing the risk of hospitalisation for the Delta variant to earlier VOC based on reported cases have presented descriptive data for younger age groups, without providing age-specific risk estimates (15, 16). Others have been restricted to hospital cohorts, with the reported findings inconsistent between settings (17-19). A study from Denmark reported that the risk of MIS-C did not change among unvaccinated cases during a wave of Delta infections compared to when the wild-type SARS-CoV-2 variant was circulating (20).

Methods

Study setting

Norway (population 5.4 million, of whom 1.1 million <18 years) has had a broad testing strategy for COVID-19 in children since autumn 2020. Four pillars of the national pandemic response have been testing, isolation, contact tracing and quarantine. Through this framework SARS-CoV-2 tests have been available free of charge for everyone, including those with mild or no symptoms, close contacts and individuals in quarantine. Routine bi-weekly screening of school children with rapid antigen tests in areas with high transmission was undertaken for secondary school students from late-August 2021 and for primary school students from November 2021 until January 2022. Positive rapid antigen tests were confirmed with PCR. COVID-19 vaccine recommendations for children and adolescents in Norway and data on vaccination coverage by age group over time are presented in supplement A, section 1. From August 2021 there has been a general recommendation that all pregnant women in the second or third trimester get vaccinated. For women with underlying risk factors, vaccination was recommended in the first trimester (22).

Data sources and study design

We obtained data through the Norwegian national preparedness registry for COVID-19 (23). The preparedness registry contains individual-level data from different central health registries, national clinical registries, and other national administrative registries. It covers all

residents in Norway, and includes data on all laboratory-confirmed cases of COVID-19 in Norway and all hospitalisations, intensive care admissions and deaths among cases. Further details on the individual registries and data included in this study are presented in supplement A, section 2.

We conducted a cohort study, including reported cases of COVID-19 aged <18 years who tested positive from 15 March 2021 up to 30 January 2022, were unvaccinated at date of positive test and had also not previously been diagnosed with COVID-19, and had a national

identity number registered. We extracted data up to 29 March 2022, ensuring a minimum 57

Definition of variant waves

days of follow-up since last positive test.

The national laboratory database houses data on SARS-CoV-2 test results from all Norwegian microbiology laboratories. In Norway, SARS-CoV-2 variants are identified based on whole genome sequencing, Sanger partial S-gene sequencing or PCR screening targeting specific single nucleotide polymorphisms, insertions or deletions. The laboratory testing for variants of SARS-CoV-2 in Norway has been described in further detail elsewhere (24). Using data from the national laboratory database we identified different variant waves based on date of positive test. The distribution of different variants among cases <18 years over time in Norway is presented in Figure 1, with the underlying data available in supplement B. We defined the Alpha dominant wave as week 11–20 (15 March–23 May) 2021, the Delta dominant wave as week 35–48 (30 August–5 December) 2021 and the Omicron dominant wave as week 2–4 (10–30 January) 2022. In the Omicron wave, sublineage BA.1 was predominant (25).

Severity outcome definitions

Our severity outcomes of interest were: 1) admission to hospital with acute COVID-19 (regardless of main cause of admission) ≤14 days after positive test, 2) admission to hospital ≤14 days after positive test where acute COVID-19 was the reported main cause of admission and 3) admission to hospital with MIS-C, defined as patients registered with the International Classification of Diseases-10 diagnosis code U10.9. Clinical criteria for the diagnosis of MIS-C cases in Norway are based on the World Health Organisation case definition, as per national paediatric guidelines (26).

Data analysis

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

We described cases by variant wave, severity outcome, demographic characteristics and underlying comorbidities. We also described other outcomes among hospitalised patients including length of stay (LoS) in hospital and admission to an intensive care unit (ICU), as well as all deaths in the study cohort. For our three severity outcomes, we calculated adjusted risk ratios (aRR) with 95% confidence intervals (CIs) using multivariable log-binomial regression. Explanatory variables to analyse differences in our outcomes included variant wave (Alpha, Delta or Omicron), age (as continuous or categorical variable), sex, country of birth, region of residence, and underlying comorbidities. The categorisation of explanatory variables is presented in Table 1 and further detailed in Supplement A, section 2. Explanatory variables were first checked in univariable models, and those with p<0.2 were further explored in multivariable models. Explanatory variables were further categorised in some models to best fit the data, for example a dichotomous variable for underlying comorbidities (yes/no). We maintained the variant wave variable in each multivariable analysis, even if not significant. We used Akaike Information Criteria and the likelihood ratio test to check model fit. We ran models for each variant combination (Delta vs. Alpha, Omicron vs. Alpha, Omicron vs. Delta) for all cases <18 years, as well as for the age subgroups <1, 1–11 and 12– 17 years. For the age group 12–17 years, we also conducted a sensitivity analysis, including

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

year of age, 44 (45%) were female and 83 (86%) had no registered comorbidity. Of the 48 <1 year, 32 (67%) were <3 months of age, and 42 (88%) were <6 months of age. In the Alpha, Delta and Omicron waves, 21 (0.2%), 28 (0.07%) and 48 (0.06%) cases <18 years were hospitalised with acute COVID-19 as main cause ≤14 days after positive test, respectively (Table 1, Table 2). The risk of hospitalisation with acute COVID-19 as main cause was lower in the Delta (aRR: 0.53, 95% CI: 0.30-0.93) and Omicron wave (aRR: 0.40, 95% CI: 0.24–0.68) compared to the Alpha wave. This was explained by the age group <1 year (aRR Delta compared to Alpha: 0.28, 95% CI: 0.16-0.89; aRR Omicron compared to Alpha: 0.41, 95% CI: 0.20–0.81). Results also suggested a decreased risk in cases aged 1–11 years in the Omicron wave compared to the Alpha wave (aRR: 0.32, 95% CI: 0.13-0.83). We did not observe any difference in the adjusted risk in any age group in the Omicron wave compared to the Delta wave. Results for the outcome admission to hospital ≤14 days after positive test regardless of main cause were largely consistent with those for acute COVID-19 as main cause of hospitalisation, although we did observe a decreased risk in cases <18 years in the Omicron wave compared to Delta wave (aRR: 0.67, 95% CI: 0.48–0.94) (Table 2). Risk of MIS-C Twenty-eight cases of MIS-C were reported across the three waves (0.02% of all cases) (Table 2). The median age was 6.5 years (interquartile range (IQR): 4–9.5; range 1–17), 12 (43%) were female and 26 (93%) had no registered comorbidity. In the Alpha, Delta and Omicron waves, 7 (0.07%), 14 (0.03%) and 7 (0.008%) cases <18 years were diagnosed with MIS-C, respectively (Table 1, Table 2). We did not observe a significant difference in the risk of MIS-C in the Delta wave compared to the Alpha wave. The risk of MIS-C among cases <18 years was lower in the Omicron wave compared to the Alpha (aRR: 0.09, 95% CI: 0.03– 0.27) and Delta wave (aRR: 0.26, 95% CI: 0.10–0.63) (Table 2).

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

Length of hospital stay, admission to intensive care and death The median LoS among cases hospitalised with acute COVID-19 as main cause was 0.8 days (IQR: 0.4–3.2) in the Alpha wave, 1.4 days (IQR: 0.7–3.1) in the Delta wave and 1.1 days (IQR: 0.8-2.7) in the Omicron wave. Among the 28 MIS-C cases the median LoS was 4 days (interquartile range (IQR): 2-6). Data on LoS is not presented by wave for MIS-C cases due to the small number of MIS-C cases in each wave. Across all three waves, 6 (6%) cases hospitalised with acute COVID-19 as main cause and 4 (14%) MIS-C cases were admitted to ICU. This equates to 0.007% of reported cases being admitted to ICU for either acute COVID-19 or MIS-C in Norway. At the end of follow-up, there were no reported deaths among those hospitalised (either for acute COVID-19 or MIS-C), nor within 30 days of positive test among those not hospitalised. **Discussion** We find no clear evidence of a difference in the risk of hospitalisation due to acute COVID-19 among cases <18 years in the Omicron wave compared to the Delta wave. Our results are in line with similar national studies from both England (5) and Denmark (12). The study in England, which included over 300,000 COVID-19 cases and 1,500 hospitalisations <20 years, did suggest a potentially small decrease in the risk of hospitalisation for Omicron compared to Delta ≤14 days after positive test among unvaccinated 10–19-year-olds (adjusted hazard ratio: 0.78, 95% CI: 0.60–1.00). We did find a lower risk for hospitalisation regardless of main cause in the Omicron wave compared to the Delta wave. However, our results for this indicator should be interpreted with caution as it will include patients admitted for non-

COVID-19 related causes. We find no difference in the risk of hospitalisation with COVID-

19 as main cause in the Omicron wave compared to the Delta wave.

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

The risk of hospitalisation with acute COVID-19 among cases <1 year was lower in the Delta and Omicron waves, compared to the Alpha wave. As the majority of hospitalised cases <1 year across the three waves were <3 months old, the decrease in risk may be related to protection offered to infants born to mothers vaccinated during pregnancy (27). Vaccination during pregnancy was first generally recommended in Norway before the start of the Delta wave. Conversely, we did not a see a difference in the risk of hospitalisation with acute COVID-19 among cases <1 year between the Omicron and Delta waves. This may reflect higher vaccination coverage among pregnant women, but lower vaccine effectiveness in the Omicron wave (7). Compared to other VOC, the Omicron variant has been shown to replicate more easily in the upper respiratory tract but less well in the lungs (28). In this study we could not explore whether the clinical presentation of children hospitalised with Omicron had changed, compared to previous variant waves. There have been reports of an increase in upper respiratory complications, such as croup, among young children since Omicron became dominant (13, 14). Such changes in the clinical presentation of hospitalised paediatric COVID-19 patients would have important implications for future hospital capacity planning and management of paediatric patients as Omicron circulates. Previous studies from the USA and Denmark estimated the incidence of MIS-C (defined based on the case definition from the Centers for Disease Control and Prevention) to be between 1 in 3,000 to 1 in 4,000 children infected with the wild-type SARS-CoV-2 variant (29, 30). A subsequent study from Denmark found that this risk did not change among unvaccinated cases during a wave of Delta infections (20). We find that the incidence of MIS-C (based on the case definition from the World Health Organisation) in Norway during the Delta wave was approximately 1 in 3,000 cases who were unvaccinated and had not been previously diagnosed with COVID-19. This decreased to 1 in 12,000 in the Omicron wave, an

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

estimated 75% decrease (95% CI: 37%–90%) in risk. This may suggest a lower intrinsic risk of MIS-C for Omicron compared to Delta. This is an encouraging finding, especially given evidence that this risk may be further reduced through vaccination. Studies from Denmark and the USA have estimated the effectiveness of two doses of Comirnaty[®] against MIS-C to be 91%–94% during periods of Delta dominance (20, 31). In this study, when we included vaccinated cases 12-17 years in a sensitivity analysis, no reported MIS-C cases had completed a two-dose primary vaccination series ≥ 7 days before positive test (supplement A, section 3). This is in line with another study from France (32). However, it remains to be seen if the same level of vaccine effect against MIS-C is maintained during a period of Omicron dominance. Omicron has been linked to an increase in breakthrough infections (7, 33) and lower vaccine effectiveness against some severity outcomes among children and adolescents 5–17 years (34). The proportion of MIS-C cases admitted to ICU in our study is notably lower than reported by others (11, 20, 35). Here, differences in the settings, definition of MIS-C cases and the definition of ICU admission need to be considered. For example, our definition of ICU admission will exclude stays in intermediate observation posts in a paediatrics unit. In this study we have analysed national registry data from a setting with a broad COVID-19 testing strategy among children and adolescents. Hospitals in Norway functioned within capacity during the study period. Criteria for hospitalisation and isolation for COVID-19 patients, and clinical criteria for the diagnosis of MIS-C, were consistent. An important limitation with severity studies based on reported COVID-19 cases is that undiagnosed cases will affect reported outcome proportions, while systematic differences in undiagnosed cases between groups may affect comparisons. In our study, this is particularly relevant for the comparison of the Alpha wave to other variant waves. The testing strategy was enhanced after the Alpha wave, thus a higher proportion of asymptomatic and mild cases may have been diagnosed among school-age children and adolescents in the Delta and

Omicron waves. Also, the small number of outcomes must be considered, which restricted further exploration of our results. Given the low incidence of severe outcomes among child and adolescent COVID-19 cases, which may be further reduced through vaccination (20, 31, 34, 36), analyses of pooled data from several countries or meta-analyses could provide more precise estimates that can better elucidate differences in the risk of these outcomes between VOC in younger age groups. Further, we have based the analysis on variant waves, not cases with known data. However, in models for all COVID-19 cases reported in Norway, results based on these waves were consistent with analyses based on cases with known variant in periods when one variant was superseding another (see supplement A, section 4). Finally, we analysed an Omicron wave when the sublineage BA.1 was the dominant circulating variant. Further studies are still needed to establish differences in disease severity between different Omicron sublineages.

Conclusion

We found no evidence of a difference in the risk of hospitalisation due to acute COVID-19 among unvaccinated cases <18 years for Omicron compared to Delta in Norway, but a reduced risk of hospitalisation among cases <1 year in Omicron and Delta waves, compared to the Alpha wave. Results also suggest a decrease in the risk of MIS-C among those infected with the Omicron variant compared to the Delta and Alpha variant.

Acknowledgements

First and foremost, we wish to thank all those who have helped establish and/or report data housed in the national emergency preparedness registry for COVID-19 at the Norwegian Institute of Public Health. We would also like to specifically thank Trude Lyngstad, Jostein Starrfelt, Elina Seppälä, Mari Grøsland and 'Team Riskgroup' at the Norwegian Institute of Public Health for their assistance in the cleaning of the data from the different registries, and

additionally Trude Lyngstad for her assistance in the production of Figure S1.

References

- 1. World Health Organisation. Tracking SARS-CoV-2 variants. 2022 [cited 2022 Mar 22]. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
- 2. Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro Surveill. 2021;26(24).
- 3. Lyngse FP, Kirkeby CT, Denwood M, Christiansen LE, Mølbak K, Møller CM, et al. SARS-CoV-2 Omicron VOC Transmission in Danish Households. Medrxiv. 2022. doi: https://doi.org/10.1101/2022.01.28.22270044
- 4. Veneti L, Seppala E, Larsdatter Storm M, Valcarcel Salamanca B, Alnes Buanes E, Aasand N, et al. Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 May 2021. PLoS One. 2021;16(10):e0258513.
- 5. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022. doi: https://doi.org/10.1016/S0140-6736(22)00462-7
- 6. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385(7):585-94.
- 7. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022. doi: https://doi.org/10.1056/NEJMoa2119451
- 8. Veneti L, Boas H, Brathen Kristoffersen A, Stalcrantz J, Bragstad K, Hungnes O, et al. Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. Euro Surveill. 2022;27(4).
- 9. World Health Organisation. COVID-19 Weekly Epidemiological Update, Edition 81. 2022 [cited 2022 Mar 22]. Available at: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-march-2022
- 10. Rubens JH, Akindele NP, Tschudy MM, Sick-Samuels AC. Acute covid-19 and multisystem inflammatory syndrome in children. BMJ. 2021;372:n385.
- 11. Harwood R, Yan H, Talawila Da Camara N, Smith C, Ward J, Tudur-Smith C, et al. Which children and young people are at higher risk of severe disease and death after hospitalisation with SARS-CoV-2 infection in children and young people: A systematic review and individual patient meta-analysis. EClinicalMedicine. 2022;44:101287.
- 12. Bager P, Wohlfahrt J, Bhatt S, Edslev SM, Sieber RN, Ingham AC, et al. Reduced Risk of Hospitalisation Associated With Infection With SARS-CoV-2 Omicron Relative to Delta: A Danish Cohort Study. SSRN. 2022. doi: http://dx.doi.org/10.2139/ssrn.4008930

- 13. Martin B, Dewitt PE, Russell S, Sanchez-Pinto LN, Haendel MA, Moffitt R, et al. Acute upper airway disease in children with the omicron (B.1.1.529) variant of SARS-CoV2: a report from the National COVID Cohort Collaborative (N3C). Medrxiv. 2022. doi: https://doi.org/10.1101/2022.01.27.22269865
- 14. Tun□ EM, Shin CKJ, Usoro E, Thomas-Smith SE, Trehan I, Migita RT, et al. Croup during the COVID-19 Omicron Variant Surge. Medrxiv. 2022. doi: https://doi.org/10.1101/2022.02.02.22270222
- 15. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis. 2021. doi: https://doi.org/10.1016/S1473-3099(21)00475-8
- 16. Fisman DN, Tuite AR. Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada. CMAJ. 2021;193(42):E1619-E25.
- 17. Martin B, DeWitt PE, Russell S, Anand A, Bradwell KR, Bremer C, et al. Characteristics, Outcomes, and Severity Risk Factors Associated With SARS-CoV-2 Infection Among Children in the US National COVID Cohort Collaborative. JAMA Netw Open. 2022;5(2):e2143151.
- 18. Yilmaz Celebi M, Kiymet E, Boncuoglu E, Sahinkaya S, Cem E, Duzgol M, et al. Evaluation of childhood hospitalization rates and degree of severity of SARS-CoV-2 variants, including B.1.1.7 (Alpha), B.1.315/P.1 (Beta/Gamma), and B.1.617.2 (Delta). J Med Virol. 2022. doi: https://doi.org/10.1002/jmv.27587
- 19. Shoji K, Akiyama T, Tsuzuki S, Matsunaga N, Asai Y, Suzuki S, et al. Comparison of the clinical characteristics and outcomes of COVID-19 in children before and after the emergence of Delta variant of concern in Japan. J Infect Chemother. 2022;28(4):591-594.
- 20. Nygaard U, Holm M, Hartling UB, Glenthøy J, Schmidt LS, Nordly SB, et al. Multisystem Inflammatory Syndrome in Children Following the SARS-CoV-2 Delta Variant in Denmark: Clinical Phenotype and Risk by Vaccination Status and Compared to the Pre-Delta COVID-19 Era. SSRN. 2022. doi: http://dx.doi.org/10.2139/ssrn.4031587
- 21. Veneti L, Valcarcel Salamanca B, Seppala E, Starrfelt J, Storm ML, Bragstad K, et al. No difference in risk of hospitalization between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway. Int J Infect Dis. 2022;115:178-84.
- 22. Norwegian Institute of Public Health. Coronavirus vaccine information for the public. 2022 [cited 2022 Mar 22]. Available from: https://www.fhi.no/en/id/vaccines/coronavirus-immunisation-programme/who-will-get-coronavirus-vaccine-first/
- 23. Norwegian Institute of Public Health. Emergency preparedness register for COVID-19 (Beredt C19). 2022 [cited 2022 Mar 22]. Available from: https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19/
- 24. Norwegian Institute of Public Health. Påvisning og overvåkning av SARS-CoV-2-virusvarianter. Oslo: Norwegian Institute of Public Health. 2022 [cited 2022 Mar 22].

Available at: https://www.fhi.no/nettpub/coronavirus/testing/pavisning-og-overvakning-av-sars-cov-2-virusvarianter/

- 25. Norwegian Institute of Public Health. Ukerapport uke 7 2022. 2022 [cited 2022 Mar 22]. Available at:
- $\frac{https://www.fhi.no/contentassets/8a971e7b0a3c4a06bdbf381ab52e6157/vedlegg/2022/ukerapport-uke-7-14.02---20.02.22.pdf}{}$
- 26. Norwegian Society of Pediatricians. Inflammatorisk multisystemsyndrom ved covid-19 (MIS-C). 2022 [cited 2022 Mar 22]. Available at: https://www.helsebiblioteket.no/pediatriveiledere?menuitemkeylev1=5962&menuitemkeylev2=5966&key=271455
- 27. Halasa NB, Olson SM, Staat MA, Newhams MM, Price AM, Boom JA, et al. Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months 17 States, July 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):264-70.
- 28. Hui KPY, Ho JCW, Cheung MC, Ng KC, Ching RHH, Lai KL, et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature. 2022. doi: https://doi.org/10.1038/s41586-022-04479-6
- 29. Payne AB, Gilani Z, Godfred-Cato S, Belay ED, Feldstein LR, Patel MM, et al. Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2. JAMA Netw Open. 2021;4(6):e2116420.
- 30. Holm M, Hartling UB, Schmidt LS, Glenthoj JP, Kruse A, Rytter MH, et al. Multisystem inflammatory syndrome in children occurred in one of four thousand children with severe acute respiratory syndrome coronavirus 2. Acta Paediatr. 2021;110(9):2581-3.
- 31. Zambrano LD, Newhams MM, Olson SM, Halasa NB, Price AM, Boom JA, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years United States, July-December 2021. MMWR Morb Mortal Wkly Rep. 2022;71(2):52-8.
- 32. Levy M, Recher M, Hubert H, Javouhey E, Flechelles O, Leteurtre S, et al. Multisystem Inflammatory Syndrome in Children by COVID-19 Vaccination Status of Adolescents in France. JAMA. 2022;327(3):281-3.
- 33. Chen LL, Chua GT, Lu L, Chan BP, Wong JS, Chow CC, et al. Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine. Emerg Microbes Infect. 2022;11(1):543-7.
- 34. Klein NP, Stockwell MS, Demarco M, Gaglani M, Kharbanda AB, Irving SA, et al. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years VISION Network, 10 States, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(9):352-8.

- 35. Miller AD, Zambrano LD, Yousaf AR, Abrams JY, Meng L, Wu MJ, et al. Multisystem Inflammatory Syndrome in Children-United States, February 2020-July 2021. Clin Infect Dis. 2021. doi: https://doi.org/10.1093/cid/ciab1007
- 36. Olson SM, Newhams MM, Halasa NB, Price AM, Boom JA, Sahni LC, et al. Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents. N Engl J Med. 2022;386(8):713-23.

Tables and Figures

Figure 1. Reported COVID-19 cases aged <18 years in Norway with known and unknown variant (bars, left y-axis), and proportion of cases with known variant that were the Alpha, Delta or Omicron variant of concern (lines, right y-axis), by week, 1 January 2021 – 6 February 2022.

The data behind the figure are available in supplement B. During the Alpha wave (week 11–20 2021), the proportion of cases that were known to be infected with Alpha ranged from 86%–95% of cases with known variant, however, the vast majority of other cases with known variant were reported as 'probable variant of concern'. In Norway, there was minimal circulation of other defined variants of concern (Beta, B.1.351 and Gamma, P.1), thus is it is reasonable to assume that most cases reported as 'probable variant of concern' were also the Alpha variant. Taking these cases into account the proportion infected with Alpha among

those with known variant ranges from 94%-100% in the Alpha wave.

Table 1. Characteristics of reported cases of COVID-19 aged <18 years who were unvaccinated and had also not previously been diagnosed with COVID-19, by variant wave, Norway, 15 March 2021 – 30 January 2022

		Variant wave				
Characteristics		Alpha dominated	Delta dominated	Omicron dominated		
		wave (n=10,538)	wave (n=42,362)	wave (n=82,907)		
Included weeks		11–20 2021	35-48 2021	2–4 2022		
Sex	Male	5118 (48.6%)	20575 (48.6%)	39835 (48.0%)		
	Female	5420 (51.4%)	21787 (51.4%)	43072 (52.0%)		
Age group	<1 year	267 (2.5%)	636 (1.5%)	1613 (1.9%)		
	1-5 years	2317 (22.0%)	5484 (12.9%)	19516 (23.5%)		
	6-11 years	3611 (34.3%)	22515 (53.1%)	50772 (61.2%)		
	12-15 years	2643 (25.1%)	10191 (24.1%)	9648 (11.6%)		
	16-17 years	1700 (16.1%)	3536 (8.3%)	1358 (1.6%)		
Median age	In years (IQR)	10 (6–14)	10 (7–13)	8 (5–10)		
Born in	Yes, with at least	5510 (52.3%)	29143 (68.8%)	63225 (76.3%)		
Norway	one parent born in Norway			, ,		
	Yes, two parents	3425 (32.5%)	8387 (19.8%)	13121 (15.8%)		
	born outside of	, ,	, ,			
	Norway					
	No	1598 (15.2%)	4812 (11.4%)	6555 (7.9%)		
	Unknown	5 (<0.1%)	20 (<0.1%)	6 (<0.1%)		
Risk for	No underlying	9732 (92.4%)	39319 (92.8%)	77699 (92.6%)		
severe	comorbidities					
COVID-19 ^a	Medium-risk	756 (7.2%)	2886 (6.8%)	5897 (7.0%)		
	comorbidity					
	High-risk	50 (0.5%)	178 (0.4%)	288 (0.3%)		
	comorbidity					
Region of	Southeast	8882 (84.3%)	29564 (69.8%)	57487 (69.3%)		
residence b	West	1265 (12.0%)	5033 (11.9%)	13831 (16.7%)		
	Mid	287 (2.7%)	4669 (11.0%)	8255 (10.0%)		
	North	94 (0.9%)	3057 (7.2%)	3270 (3.9%)		
	Unknown	10 (<0.1%)	39 (<0.1%)	64 (<0.1%)		
Admission to	No	10507 (99.7%)	42303 (99.9%)	82819 (99.9%)		
hospital	Yes, ≤14 days	30 (0.3%)	58 (0.1%)	86 (0.1%)		
	after positive test					
	Yes, 15–28 days	1 (<0.1%)	1 (<0.1%)	2 (<0.1%)		
	after positive test					
Admission to	No	10517 (99.8%)	42334 (99.9%)	82858 (99.9%)		
hospital with	Yes, ≤14 days	21 (0.2%)	28 (<0.1%)	48 (<0.1%)		
COVID-19 as	after positive test					
main cause of	Yes, 15–28 days	0 (0.0%)	0 (0.0%)	1 (<0.1%)		
admission	after positive test					
Diagnosed	No	10531 (99.9%)	42348 (100.0%)	82900 (100.0%)		
with MIS-C	Yes	7 (<0.1%)	14 (<0.1%)	7 (<0.1%)		

COVID-19: coronavirus disease; MIS-C: Multisystem Inflammatory Syndrome in Children;

IQR: interquartile range.

348 349

345 346

350 351

352

353

354

355

356

357 358

359

360

361 362

363

364

365

Nordland, and Troms and Finnmark.

367

368

medRxiv preprint doi: https://doi.org/10.1101/2022.03.29.22273093; this version posted March 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

					0.97)	$2.01)^{b,c,d}$			0.64)	0.83) b,c	1.55)	$1.35)^{b,c,d}$
12-17 years 4/434:	4/4343	< 0.1	8/13727	< 0.1	0.63	a	3/11006	< 0.1	0.30	a	0.47	а
					(0.19-				(0.07 -		(0.12 -	
					2.10)				1.32)		1.76)	
All <18 years 21/109	21/10538	0.2	28/42362	< 0.1	0.33	0.53	48/82907	< 0.1	0.29	0.40	0.88	0.76
					(0.19-	(0.30-			(0.17-	(0.24-	(0.55-	(0.47-
					0.58)	0.93) b,c			0.48)	0.68) b,c	1.40)	$1.23)^{b,c}$
Outcome: MIS-C												
<1 year	0/267	0.0	0/636	0.0	-	-	0/1613	0.0	-	-	-	-
1-11 years	6/5928	0.1	11/27999	< 0.1	0.39	a	7/70288	< 0.1	0.10	a	0.25	а
					(0.14-				(0.03 -		(0.10-	
					1.05)				0.29)		0.65)	
12-17 years 1/43a	1/4343	< 0.1	3/13727	< 0.1	0.95	a	0/11006	0.0	-	-	-	-
					(0.10 -							
					9.12)							
All <18 years	7/10538	< 0.1	14/42362	< 0.1	0.50	a	7/82907	< 0.1	0.13	0.09	0.26	а
					(0.20 -				(0.04-	(0.03 -	(0.10 -	
					1.23)				0.36)	0.27) b,e	0.63)	

369 COVID-19: coronavirus disease; MIS-C: Multisystem Inflammatory Syndrome in Children; 95% CI: 95% confidence interval.

^a The crude model was the best model. 370

³⁷¹

b Adjusted for age.
c Adjusted for underlying comorbidities.
d Adjusted for country of birth. 372

³⁷³

^e Adjusted for region of residence. 374

